Skip to content

Replimune Group REPL Accrued Expenses

Accrued Expenses at other companies

Amgen logo
AmgenAMGN
$16.58B-3.8%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.24M-17.5%
Immunome logo
ImmunomeIMNM
$21.88M+23.9%
CG Oncology logo
CG OncologyCGON
$25.91M+65.5%
Erasca, Inc. logo
Erasca, Inc.ERAS
$19.25M+4.5%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$847K-49.6%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$919.03M+28.6%
Enterprise value$873.59M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's accrued expenses?
Replimune Group (REPL) reported accrued expenses of $40.37M in Q4 2025.
How has Replimune Group's accrued expenses changed year-over-year?
Replimune Group's accrued expenses increased by 9.8% year-over-year, from $36.76M to $40.37M.
What is the long-term trend for Replimune Group's accrued expenses?
Over 4 years (2021 to 2025), Replimune Group's accrued expenses has grown at a 51.4% compound annual growth rate (CAGR), from $8.74M to $45.92M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.